FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity
Cells · 2023
DOI: 10.3390/cells12242777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Marco Fiorillo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Tamoxifen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Ministry of Education, Universities and Research, Department of Excellence (MIUR, Italian Law 232/2016).
Abstract (Originalsprache)
Tamoxifen-resistant breast cancer cells (TamR-BCCs) are characterized by an enhanced metabolic phenotype compared to tamoxifen-sensitive cells. FoxO3a is an important modulator of cell metabolism, and its deregulation has been involved in the acquisition of tamoxifen resistance. Therefore, tetracycline-inducible FoxO3a was overexpressed in TamR-BCCs (TamR/TetOn-AAA), which, together with their control cell line (TamR/TetOn-V), were subjected to seahorse metabolic assays and proteomic analysis. FoxO3a was able to counteract the increased oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) observed in TamR by reducing their energetic activity and glycolytic rate. FoxO3a caused glucose accumulation, very likely by reducing LDH activity and mitigated TamR biosynthetic needs by reducing G6PDH activity and hindering NADPH production via the pentose phosphate pathway (PPP). Proteomic analysis revealed a FoxO3a-dependent marked decrease in the expression of LDH as well as of several enzymes involved in carbohydrate metabolism (e.g., Aldolase A, LDHA and phosphofructokinase) and the analysis of cBioPortal datasets of BC patients evidenced a significant inverse correlation of these proteins and FoxO3a. Interestingly, FoxO3a also increased mitochondrial biogenesis despite reducing mitochondrial functionality by triggering ROS production. Based on these findings, FoxO3a inducing/activating drugs could represent promising tools to be exploited in the management of patients who are refractory to antiestrogen therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
- Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester M5 4WT, UK.
ORCID-Profile: Marco Fiorillo, Daniela Bonofiglio, Francesca Luisa Conforti, Ines Barone, Catia Morelli, Diego Sisci
Förderung
- Italian Association for Cancer Research
- Ministry of Education, Universities and Research
- Department of Excellence (MIUR, Italian Law 232/2016)
- Lunella Biotech, Inc.,
- PRIN 2017
- AIRC
- BANDO PRIN 2017
- Next Generation EU—Italian NRRP
Zitieren
APA
Fiorillo, M., Ricci, E., Fava, M., Longobucco, C., Sotgia, F., Rizza, P., Lanzino, M., Bonofiglio, D., Conforti, F. L., Catalano, S., Barone, I., Morelli, C., Aquila, S., Lisanti, M. P., & Sisci, D. (2023). FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity. Cells. https://doi.org/10.3390/cells12242777
Vancouver
Fiorillo M, Ricci E, Fava M, Longobucco C, Sotgia F, Rizza P, et al. FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity. Cells. 2023. doi:10.3390/cells12242777
BibTeX
@article{Fiorillo2023,
author = {Fiorillo, Marco and Ricci, Elena and Fava, Mariarosa and Longobucco, Camilla and Sotgia, Federica and Rizza, Pietro and Lanzino, Marilena and Bonofiglio, Daniela and Conforti, Francesca Luisa and Catalano, Stefania and Barone, Ines and Morelli, Catia and Aquila, Saveria and Lisanti, Michael P and Sisci, Diego},
title = {FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12242777}
}
EUVIMED